NCT01685983View on ClinicalTrials.gov

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 30, 2011

Primary Completion Date

January 24, 2013

Study Completion Date

March 6, 2018

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone acetate

Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.

DRUG

Prednisolone

Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.

Trial Locations (8)

Unknown

Busan

Cheongju-si

Seongnam-Si, Gyeonggi-Do

Seoul

Kaohsiung City

Taichung

Taipei

Taoyuan

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01685983 - A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter